MediFind

Find a Doctor

Victoria G. Atkinson

Princess Alexandra Hospital
Female

Bio


Victoria Atkinson is in Alexandra, Australia. They have been an author on 75 peer reviewed articles and participated in 1 clinical trials in the past 15 years. Dr. Atkinson's top three areas of expertise are Melanoma, Familial Atypical Multiple Mole Melanoma Syndrome, and Metastatic Brain Tumor.

Contact

Alexandra, QLD, AU

Latest Research


Latest Advance
Study
  • Condition: Stage III Melanoma
  • Journal: The New England journal of medicine
  • Treatment Used: Dabrafenib plus Trametinib
  • Number of Patients: 870
  • Published —
In this study, researchers evaluated the 5-year outcomes of using dabrafenib plus trametinib for the treatment of stage III melanoma.
Latest Advance
Study
  • Condition: Advanced Melanoma
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Discontinuation of Anti-PD-1 Antibody Therapy
  • Number of Patients: 185
  • Published —
This study investigated the outcome of advanced melanoma patients who electively discontinued anti-PD-1 therapy with pembrolizumab or nivolumab in the absence of disease progression (PD) or treatment limiting toxicity (TLT).
Latest Advance
Study
  • Condition: Resected High-Risk Stage III Melanoma
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Pembrolizumab
  • Number of Patients: 1019
  • Published —
This study tested the safety and efficacy of using pembrolizumab to treat patients with resected high-risk stage III melanoma.
Latest Advance
Study
  • Condition: BRAF-mutant melanoma
  • Journal: Nature medicine
  • Treatment Used: Dabrafenib, trametinib and pembrolizumab
  • Number of Patients: 120
  • Published —
The study aimed to determine the effects of dabrafenib, trametinib and pembrolizumab in treating BRAF-mutant melanoma.
Latest Advance
Study
  • Condition: BRAF V600-mutated metastatic melanoma
  • Journal: Melanoma research
  • Treatment Used: Dabrafenib
  • Number of Patients: 331
  • Published —
The study researched the effects of Dabrafenib for patients with BRAF V600-mutated metastatic melanoma.
Latest Advance
Study
  • Condition: BRAF Wild-Type Advanced Melanoma
  • Journal: JAMA oncology
  • Treatment Used: Nivolumab Versus Dacarbazine
  • Number of Patients: 418
  • Published —
In this study, researchers compared the effectiveness of nivolumab versus dacarbazine for the treatment of BRAF wild-type advanced melanoma.
Latest Advance
Study
  • Condition: Solid Organ Transplant, HIV and Hepatitis B/C
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Anti-PD-1/PD-L1 Immunotherapy
  • Number of Patients: 46
  • Published —
The purpose of this study was to evaluate the safety of anti-PD-1/PD-L1 immunotherapy in cancer patients that have had an organ transplant, are infected with HIV or have hepatitis B/C.
Latest Advance
Study
  • Condition: Adenocarcinoma of Esophagus
  • Journal: Journal of surgical oncology
  • Treatment Used: Neoadjuvant Chemotherapy (nCT) or Chemoradiotherapy
  • Number of Patients: 396
  • Published —
This study compared outcomes in patients undergoing neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT) for esophageal adenocarcinoma (EAC).

All Publications
View All


Publication
Study
  • Journal: The New England journal of medicine
  • Published —
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Publication
Study
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Published —
The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.

Contact

Alexandra, QLD, AU

Insurance

Contact them to find out if they accept your insurance plan.